A5006060886- Cancer survivorship and care
- Cancer-related cognitive impairment studies
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Palliative Care and End-of-Life Issues
- Patient-Provider Communication in Healthcare
- Childhood Cancer Survivors' Quality of Life
- Blood properties and coagulation
- Family Support in Illness
- Cancer Diagnosis and Treatment
- Nutrition, Genetics, and Disease
- Lung Cancer Treatments and Mutations
- Climate Change and Health Impacts
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Amino Acid Enzymes and Metabolism
- HER2/EGFR in Cancer Research
- Polyamine Metabolism and Applications
- Cancer Research and Treatments
- Mobile Health and mHealth Applications
- Cardiovascular Health and Risk Factors
- Thermoregulation and physiological responses
- PI3K/AKT/mTOR signaling in cancer
- Metabolism, Diabetes, and Cancer
Johns Hopkins University
2010-2023
Sidney Kimmel Comprehensive Cancer Center
2010-2023
Johns Hopkins Medicine
2018-2022
University of Baltimore
2021
Propath Services (United States)
2012
GlaxoSmithKline (United States)
2012
Parkland Health & Hospital System
2012
GlaxoSmithKline (Germany)
2012
University of Minnesota
1995
St. John Medical Center
1995
We sought to evaluate the feasibility of detecting PIK3CA mutations in circulating tumor DNA (ctDNA) from plasma patients with metastatic breast cancer using a novel technique called BEAMing.
Abstract We examined the effects of a communication intervention to engage family care partners on patient portal (MyChart) use, illness understanding, satisfaction with cancer care, and symptoms anxiety in single-blind randomized trial patients treatment for breast cancer. Patient-family dyads were recruited randomly assigned self-administered checklist clarify partner role, establish shared visit agenda, facilitate MyChart access ( n = 63) or usual 55). Interviews administered at baseline,...
Abstract Many patients discontinue endocrine therapy for breast cancer due to intolerance. Identification of at risk discontinuation is challenging. The minimal important difference (MID) the smallest change in a score on patient-reported outcome (PRO) that clinically significant. We evaluated association between treatment-emergent symptoms detected by worsening PRO scores units equal MID with discontinuation. enrolled females stage 0-III initiating prospective cohort. Participants completed...
Treatment-associated symptoms drive early discontinuation of adjuvant endocrine therapy (ET) for breast cancer. We hypothesized that symptom monitoring with electronic patient-reported outcomes (ePROs) during ET will enhance detection, management, and persistence.
61 Background: Breast cancer survivor numbers are increasing due to population aging and improved treatment outcomes but many of their long-term health care needs unmet. Integrated follow-up strategies that enhance coordination, education, access survivorship resources needed provide patients with evidence-based addresses medical psychosocial after treatment. Methods: In 2008, we established the Johns Hopkins Cancer Survivorship Program representation from Schools Nursing, Public Health,...
Abstract Background: Survivorship care plans (SCPs) are strongly recommended for all breast cancer survivors to address sequelae of care, plan surveillance and screening, encourage health promotion coordination. Ongoing studies evaluating the impact SCPs in survivor populations role survivorship visits (SVs) as an intervention. Here we describe characteristics outcomes patients who participated SVs at Johns Hopkins (JH). Methods: We retrospectively reviewed charts a SV with one two nurse...
e22085 Background: Guidelines recommend that breast cancer survivors maintain a healthy body weight as obesity (BMI≥30 kg/m2) predicts worse survival outcomes. We sought to identify patient characteristics, treatment factors and adverse effects associated with in follow up of cohort women who had survivorship transition visit (SV). hypothesized those were obese at diagnosis higher frequency therapy-related complications SV. Methods: Retrospective chart review stage I-III patients SV after...
Abstract Background: Despite known benefits in reducing breast cancer (BC) recurrence and death, up to 50% of patients discontinue endocrine therapy (ET) early. Symptoms are often cited as a reason for early ET discontinuation (DC). The symptom burden during captured by patient reported outcomes (PRO) exceeds that clinicians. Methods: We initiated single arm pilot trial evaluating monitoring with PRO collected via smart phone app. Eligible women starting stage 0-III BC. Participants receive...
Abstract Purpose: To better understand the impact of cancer and treatment on outcomes guide program development, we evaluated breast survivors at risk for long-term medical psychosocial issues who participated in survivorship care visits (SVs) Johns Hopkins Hospital. Methods: We conducted a prospective survey study women with stage I-III SVs from 2010-2016. The same 56-item questionnaire administered SV follow-up included an assessment symptoms, social factors, demographics, anxiety,...